We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Armata Pharmaceuticals, Inc. (ARMP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 973 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARMP has returned about 60% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -2.3% on a year-to-date basis. This means that Armata Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 27.8%.
The consensus estimate for Actinium Pharmaceuticals' current year EPS has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 484 individual stocks and currently sits at #89 in the Zacks Industry Rank. This group has gained an average of 3.3% so far this year, so ARMP is performing better in this area.
In contrast, Actinium Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 155 stocks and is ranked #96. Since the beginning of the year, the industry has moved +10.1%.
Investors with an interest in Medical stocks should continue to track Armata Pharmaceuticals, Inc. and Actinium Pharmaceuticals. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Armata Pharmaceuticals, Inc. (ARMP - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 973 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ARMP has returned about 60% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -2.3% on a year-to-date basis. This means that Armata Pharmaceuticals, Inc. is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 27.8%.
The consensus estimate for Actinium Pharmaceuticals' current year EPS has increased 1.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 484 individual stocks and currently sits at #89 in the Zacks Industry Rank. This group has gained an average of 3.3% so far this year, so ARMP is performing better in this area.
In contrast, Actinium Pharmaceuticals falls under the Medical - Drugs industry. Currently, this industry has 155 stocks and is ranked #96. Since the beginning of the year, the industry has moved +10.1%.
Investors with an interest in Medical stocks should continue to track Armata Pharmaceuticals, Inc. and Actinium Pharmaceuticals. These stocks will be looking to continue their solid performance.